Sign Up Today and Learn More About AAVantgarde Bio Stock
Invest in or calculate the value of your shares in AAVantgarde Bio or other pre-IPO companies through EquityZen's platform.
AAVantgarde Bio Stock
AAVantgarde Bio is a clinical-stage biotechnology company that develops gene therapies for inherited retinal disorders.
About AAVantgarde Bio Stock
Founded
2021
Industries
Sales and Marketing, Design, Supply Chain and Logistics
AAVantgarde Bio Press Mentions
Stay in the know about the latest news on AAVantgarde Bio
Usher Syndrome Market Set to Grow to USD 3.20 Billion by 2032 | Coherent Market Insights
globenewswire • Nov 14, 2025
Orphan Drug Market to Reach USD 621.85 Billion by 2034, Driven by Rising Rare Disease Incidence and Innovation
globenewswire • Nov 10, 2025
In other news this week: Aspirity Partners closes €875M debut fund, AAVantgarde Bio secures €122M, Reflex Aerospace raises €50M and more
siliconcanals • Nov 08, 2025
Nexperia resumes chip shipments as Dutch government moves to end control, signaling a possible thaw in chip war with China
techstartups • Nov 08, 2025
Mastercard negotiating to buy Zero Hash
techstartups • Nov 08, 2025
AAVantgarde Bio Management
Leadership team at AAVantgarde Bio
CEO
Natalia Misciattelli
Chief Technical Officer
Nina Kotsopoulou
Join now and verify your accreditation status to gain access to:
- AAVantgarde Bio Current Valuation
- AAVantgarde Bio Stock Price
- AAVantgarde Bio Management
- Available deals in AAVantgarde Bio and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- AAVantgarde Bio Cap Table and Funding History by Share Class and Liquidity Preferences
- AAVantgarde Bio Revenue and Financials
- AAVantgarde Bio Highlights
- AAVantgarde Bio Business Model
- AAVantgarde Bio Risk Factors
- AAVantgarde Bio Research Report from SACRA Research
Trading AAVantgarde Bio Stock
How to invest in AAVantgarde Bio stock?
Accredited investors can buy pre-IPO stock in companies like AAVantgarde Bio through EquityZen funds. These investments are made available by existing AAVantgarde Bio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell AAVantgarde Bio stock?
Shareholders can sell their AAVantgarde Bio stock through EquityZen's private company marketplace. EquityZen's network includes over 400K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 49K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."